

DAFTAR PUSTAKA

- Aisyah Echa & Nadjib Mardiaty. 2017. Evaluasi Ekonomi Penggunaan Antibiotika Profilaksis Cefotaxime dan Ceftriaxone pada Pasien Operasi Seksio Sesarea di Rumah Sakit X. Departemen Administrasi Kebijakan Kesehatan, Fakultas Kesehatan Masyarakat, Universitas Indonesia. *Jurnal Ekonomi Kesehatan Indonesia*. Volume 3, Nomor 2
- Babic M and Bonomo RA, 2009. Mutation as a basis of antimicrobial resistance. In *Antimicrobial drug resistance mechanisms of drug resistance clinical and epidemiological aspects* (1) pp 65-74
- Bajpai T., Pandey M., Varma M., and Bhatambare G. S., 2017. Prevalence of TEM, SHV, and CTX-M Beta-Lactamase genes in the urinary isolates of a tertiary care hospital. In *Avicenna J. Med.* 7(1): pp 12–6.
- Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. *Nat Rev Microbiol.* 2015;13:42–51.
- Brooks, G F. 2005. *Antimicrobial Chemotherapy*, in Jawetz, Melnick & Alderberg *Medical Microbiology*. Mc Graw Hill. Pp 375
- Brooks, GF, Karen C Carroll, Janet S Butel, Stephen A Morse and Timothy A Mietzner. 2013. *Antimicrobial Chemotherapy* in Jawetz, Melnick & Alderberg *Medical Microbiology*, 26th Ed, chapter 28, Mc Graw Hill : pp 376
- Bush K., Jacoby G.A., and Medeiros A.A., 1995. A Functional Classification Scheme for β -Lactamases and Its Correlation with Molecular Structure. *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*, , p. 1211-33
- Bush K., 2009. The Importance of β Lactamases to the Development of New β Lactams. In *Antimicrobial Drug Resistance: mechanisms of Drug Resistance, Clinical and Epidemiological Aspect*. pp.135-44
- Cantón R., Valverde A., Novais A., Baquero F., Coque T., 2007. Evolution and current situation of ESBL. *Enferm Infecc Microbiol Clin* ; 25(S2): 2–10
- Colodner R., Rock W., Chazan B., *et al.*, 2004. Risk Factor for the Development of Extended-Spectrum Beta-Lactamase-Producing Bacteria in Nonhospitalized Patients. *Eur J.Clin. Microbiol Infect Dis.* (23)pp.163-7
- CLSI M100-S24, 2016. *Performance Standards for Antimicrobial Susceptibility Testing*; Twenty-Fourth Informational Supplement pp.111-2
- Davies J and Wright G. 1997. Bacterial Resistance to Aminoglycoside Antibiotics. *Trends in Microbiology* 1997;5:234-39.

- Desjardins P, Picard, B., Kaltenbock, B., Elion, J., Denamur, E., 1995, Sex in *Escherichia coli* does not disrupt the clonal structure of the population: evidence from random amplified polymorphic DNA and restriction fragment-length polymorphism, *J Mol Evol.*, 41:440-8.
- De la Fuente-Nunez C, Reffuveille F, Fernandez L, Hancock RE. *Curr Opin Microbiol.* 2013;16:580–589.
- Dhillon RHP and Clark J, 2012. ESBLs: A Clear and Present Danger? *Critical Care Research and Practice*. Diunduh dari <https://www.hindawi.com/journals/ccrp/2012/625170/> pada 11 Nopember 2016
- Diana Doyle, Gisele Peirano, Christine Lascols, Tracie Lloyd, Deirdre L. Church, and Johann D. D. Pitout, 2012. Laboratory Detection of *Enterobacteriaceae* That Produce Carbapenemases, *Journal of Clinical Microbiology* p. 3877–3880
- Donnenberg MS., 2002, *Escherichia coli*. Virulence mechanisms of a versatile pathogen. San Diego, California: *Academic Press*.
- Drlica , 2003. The mutant selection window and antimicrobial resistance. *J Antimicrob Chemoth* 52: 11–17
- Durham S.H., Aq-id B., Wingler M.J. and Eiland L.S., 2017, Appropriate Use of Ceftriaxone in the Emergency Department of a Veteran ' s Health Care System, *Journal of Pharmacy Technology*, 33(6), 215 –218.
- Ejrnæs. K, 2011. Bacterial characteristics of importance for recurrent urinary tract infections caused by *Escherichia coli*. Diunduh dari <https://www.ncbi.nlm.nih.gov/pubmed/21466767> pada tanggal 16 Oktober 2016
- Fontana R., Canepari P., Lleò M.M., Satta G. (1990). Mechanisms of resistance of enterococci to beta-lactam antibiotics. *European Journal of Clinical Microbiology & Infectious Diseases*. 9 (2): 103–105. doi:10.1007/BF01963633
- Fux CA, Stoodley P, Shirtliff M, Costerton JW, 2009. The functional resistance of bacterial biofilm. In *Antimicrobial Drug Resistance: mechanisms of Drug Resistance, Clinical and Epidemiological Aspect*. pp.121 – 31
- Gallo G. dan Puglia A.M., 2014. Antibiotics and Resistance: A Fatal Attraction. *Antibiotics: Target, Mechanisms, and Resistance*. Wiley VCH Weinheim Germany. pp.73-108
- Garneau-Tsodikova, S., & Labby, K. J. (2016). Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. *MedChemComm*, 7(1), 11–27. doi:10.1039/c5md00344j

- Hauser, A.R. and Ozer. E.A., 2011, *Pseudomonas aeruginosa*. *Nature Reviews. Microbiology*
- Jawetz Melnick,&Adelberg's, 2016, *Medical Microbiology*.27th Megraw- Hill Education. Unted State. Hal: 231
- Karami N, Nowrouzian F, Adlerberth I, and Wold AE.Tetracycline Resistance in *Escherichia coli* and Persistence in the Infantile Colonic Microbiota.*Antimicrobial Agents and Chemotherapy*. 2006; 156–61
- Kaur J., Chopra S., Sheevani, Mahajan G., 2013. Modified Double Disc Synergy Test to Detect ESBL Production in Urinary Isolates of *Escherichia coli* and *Klebsiella pneumoniae*.In *Journal of Clinical and Diagnostic Research*. Vol-7(2): 229-33
- Khurana S, Mathur P, Kapil A, Valsan C, and Behera B. 2017. Molecular Epidemiology of Beta-lactamaseproducing Nosocomial Gram-negative Pathogensfrmo North and South Indian Hospitals. *JournalMedical Microbiology*. 2017; 66(7): 999-1004.
- Kocsis B and Szabó D. 2013. Antibiotic Resistance Mechanisms In Enterobacteriaceae. *Microbial pathogens and strategies for combating them: science, technology and education*. pp. 251-257.
- Kotra LP, Haddad J, Mobashery S. 2000. Aminoglycosides: Perspectives on mechanisms of action and resistance and strategies to counter resistance. *Antimicrob Agents Chemother* 44: 3249–3256.
- Lautenbach E, Patel J.B., Bilker W.B., Edelstein P.H., Fisman N.O., 2001. Extended spectrum beta lactamse producing *Escherechia coli* and *Klebsiella pneumoniae*: Risk factor for infection and impact of resistance on outcomes.*Clin. Infect. Dis*. 32: 1162-71
- Levin, B. R., & Rozen, D. E. (2006). Non-inherited antibiotic resistance. *Nature Reviews Microbiology*, 4(7), 556–562. doi:10.1038/nrmicro1445
- Liao, CH., Sheng, WH., Wong, JT., Sun, HY., Wang, HK., Hsueh, PR. *et al.*, 2006, In Vitro Activities of 16 Antimicrobial Agent Againts Clinical Isolates of Extended-Spectrm Beta-Lactamase Producing *Escherichia coli* and *Klebsiella pneumoniae* in Two Regional Hospital in Taiwan, *Journal of Microbiology, Immunology and Infection*, 39: 59-66
- Li X.Z., Plesiat P., and Nikaido H., *Clin. Microbiol. Rev.*, 2015, **28**, 337-418.
- Michael D. Reed, Robert C. Stern, Cheryl A. O'brien, Toyoko S. Yamashita, Carolyn M. Myers, Jeffrey L. Blumeri. 1985. Pharmacokinetics Of Imipenem And Cilastatin In Patients With Cystic Fibrosis., . *Antimicrobial Agents And Chemotherapy*. 27 (4): 583–588.

- Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. 1999. Aminoglycosides: Activity and resistance. *Antimicrob Agents Chemother* 43: 727–737.
- Moore,R.A. DeShazer D, Reckseidler S., Weissman A., and Woods D. E, 1999. *Antimicrob. Agents Chemother.*, 1999, **43**, 465-470
- Mulley,MR, Christianson S,Bryce E, Simor AE, Boyd D, Agostini MO, Paton S, 2004. Ambler Class A Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* and *Klebsiella spp.* in Canadian Hospitals. In antimicrobial agents and chemotherapy 48(4) pp. 1204–14
- Murray P. R., Baron E. J., Landry M. L., Jorgenen J.H, Pfaller M.A., 2007. "Manual of Clinic Microbiology "9th edition; p. 734-743, 1083-1084, *ASM Press*, Washington DC.
- Nawakasari N, Nugraheni A Y, 2017. Evaluasi Penggunaan Antibiotik pada Pasien Infeksi Saluran Kemih di Instalasi Rawat Inap RSUP X di Klaten Tahun 2017. Fakultas Farmasi, Universitas Muhammadiyah Surakarta. *Pharmacon: Jurnal Farmasi Indonesia. Vol. 16, No. 1, (2019). ISSN 1411-4283*
- Nikaido H., *Adv. Enzymol. Relat. Areas Mol. Biol.*, 2011, **77**, 1-60.
- Paterson, D.L. and Bonomo, R.A. 2005 Extended-Spectrum Beta-Lactamases: A Clinical Update. *Clinical Microbiology Reviews*, 18, 657-686. <http://dx.doi.org/10.1128/CMR.18.4.657-686>.
- Ramirez MS, Tolmasky ME. 2010. Aminoglycoside modifying enzymes. *Drug Resist Updat* 13: 151–171.
- Reshes G., Vanounou S., Fishov I., and Feingold M., 2008.Cell Shape Dynamics in *Escherichia coli*. In *Biophys J.* 94(1): 251–64. Diunduh dari <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2134870/> pada tanggal 16 Oktober 2016
- Roi PH, 2009. Genetic mechanisms of transfer of drug resistance. In *Antimicrobial Drug Resistance: mechanisms of Drug Resistance, Clinical and Eidemiological Aspect.* pp.53-64
- Ruben Vardanyan, Victor J. Hruby. 2006. *Synthesis of essential drugs.* Elsevier Science. ISBN 978-0-444-52166-8.
- RyanK.J., Kay C.G., 2010, " Sherris Medical Microbiology" 5th edition;p. 410, p. 422-423, p. 617-623, *McGraw Hill Medical*, New York.

- Severin JA¹, Lestari ES, Kloezen W, Lemmens-den Toom N, Mertaniasih NM, Kuntaman K, Purwanta M, Duerink DO, Hadi U, van Belkum A, Verbrugh HA, Goessens WH; “Antimicrobial Resistance in Indonesia, Prevalence and Prevention” (AMRIN) study group. 2012. Faecal carriage of extended-spectrum B- lactamase-producing Enterobacteriaceae among humans in Java, Indonesia, in 2001-2002, *Tropical Medicine and International Health*, 17(4), pp. 455-461. doi: 10.11115.1365-3156.2011.02949.x.
- Sherry F. Queener, J. Alan Webber. 1986. Beta-lactam antibiotics for clinical use. Informa Healthcare. ISBN 978-0-8247-7386-1.
- Siswandono, 2008. Kimia Medisinal ed 2. Surabaya: Airlangga University Press (Hal: 134)
- Skiada A, Markogiannakis A, Plachouras D, Daikos GL. *Int J Antimicrob Agents*. 2011;37:187–193.
- Stubbings W, Bostock J, Ingham E, Chopra I. 2006. Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in *Escherichia coli*. *J Antimicrob Chemother* 58: 444–448.
- Struelens, M.J., 1998, The Epidemiology of Antimicrobial Resistance in Hospital Acquired Infections : Problems and Possible Solutions, *BMJ*, 317: 652 – 659
- Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, 2016. Fluoroquinolone-Resistant and Extended-Spectrum β -Lactamase-Producing *Escherichia coli* Infections in Patients with Pyelonephritis, United States. *Emerging Infectious Diseases* 22(9); 1594-604
- Tang, S. S., Apisarnthanarak, A., & Hsu, L. Y. 2014. Mechanisms of β -lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. *Advanced Drug Delivery Reviews*, 78, 3–13. doi:10.1016/j.addr.2014.08.003
- Tenover FC, Kalsi RK, Williams PP, Carey RB, Stocker S, Lonsway D, Rasheed JK, Biddle JW, McGowan JE Jr, Hanna B, 2006. Carbapenem resistance in
- Todar K, 2011. Bacterial Resistance to Antibiotics. Todar’s online text book of bacteriology. Diunduh dari http://textbookofbacteriology.net/resantimicrobial_3.html pada 11 Nopember 2016
- Torok E., Moran E., Cooke F., 2010, “Oxford Handbook Infection Disease and Microbiology” p. 68-69, p. 78-79, *Oxford University Press*, New York.
- Tortora G.J, Funke BR, Christine LC. *Microbiology an Introduction*, 8th Edition, Pearson Education, Inc. San Fransisco, CA 2004; 599 *Klebsiella pneumoniae*

not detected by automated susceptibility testing. In *Emerg. Infect. Dis.* 12(8):1209-13

59

- Tham Johan. 2012. Extended-Spectrum Beta-Laktamase producing Enterobacteriaceae : Epidemiology, Risk Faktors, and Duration of Tham Johan. 2012. Carriage. Swedia. Lund University, pp 11-12.
- Thomson KS, Sanders CC, Moland ES. 1992. Detection of extended spectrum β Lactamases in members of the family *Enterobacteriaceae* comparison of the double disk and three dimensional test. *Antimicrob Agents Chemother* 1992; 36: 1877-82.
- Tille PM, 2014. *Bailey & Scott's Diagnostic Microbiology* 13th ed. Elsevier St. Louis, Missouri.pp.307-28
- Tolun V, Kucukbasmac O, Akbulut DT, Catal C, Kucuker MA, and Ang O, 2004 Relationship between ciprofloxacin resistance and extended-spectrum β -lactamase production in *Escherichia coli* and *Klebsiella pneumoniae* strains. In *European Society of Clinical Microbiology and Infectious Diseases, CMI*, 10, 70–83. Diunduh dari [http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X\(14\)63697-1/pdf](http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)63697-1/pdf) pada 11 Nopember 2016
- Wachino J, Arakawa Y. 2012. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: An update. *Drug Resist Updat* 15: 133–148.
- Walker KE, Mahon CR, Lehman D, Manuselis G, 2015. *Enterobacteriaceae*. In *Text book of diagnostic microbiology* 5th ed. pp 420-54
- Wiegand I, Geiss HK, Mack D, Stürenburg E, Seifert H, 2007. Detection of extended-spectrum beta-lactamases among *Enterobacteriaceae* by use of semiautomated microbiology systems and manual detection procedures. In *J. Clin. Microbiol.* 45(4):1167-74
- Wilson DN. 2014. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. *Nat Rev Microbiol* 12: 35–48.
- Woodford N., Turton J.F., Livermore D.M., 2011. Multi resistant gram negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. *FEMS Microbiol. Rev.*;35:736–55
- Zeng X, Lin J, 2013. Beta-lactamase induction and cell wall metabolism in Gram-negative bacteria. Diunduh dari <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660660/> pada 20 Oktober 2016

Zhanel GG, Hoban DJ, Harding GK. 1991. The postantibiotic effect: A review of in vitro and in vivo data. *DICP* 25: 153–163.